| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
395,710,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Moderna is a biotechnology company creating medicines based on messenger RNA (mRNA) to improve the lives of patients. mRNA medicines are designed to direct the body's cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. Co.'s platform builds on basic and applied mRNA science, delivery technology, and manufacturing, providing it the capability to pursue in parallel a pipeline of new development candidates. Co. is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
207,577 |
271,295 |
1,198,961 |
5,996,324 |
| Total Sell Value |
$21,215,706 |
$27,590,156 |
$140,537,830 |
$874,362,347 |
| Total People Sold |
5 |
6 |
6 |
10 |
| Total Sell Transactions |
21 |
30 |
81 |
298 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Andres Juan |
See remarks |
• • – |
2022-12-14 |
4 |
OE |
$20.93 |
$41,860 |
D/D |
2,000 |
14,803 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-14 |
4 |
AS |
$199.88 |
$8,462,856 |
D/D |
(40,000) |
5,411,946 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-14 |
4 |
OE |
$0.99 |
$39,600 |
D/D |
40,000 |
5,451,946 |
|
- |
|
| Afeyan Noubar |
Director |
– • – |
2022-12-14 |
4 |
AS |
$195.00 |
$1,950,000 |
D/D |
(10,000) |
2,287,209 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-08 |
4 |
AS |
$179.12 |
$1,791,200 |
I/I |
(10,000) |
6,594,880 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-08 |
4 |
AS |
$182.19 |
$7,322,501 |
D/D |
(40,000) |
5,411,946 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-08 |
4 |
OE |
$0.99 |
$39,600 |
D/D |
40,000 |
5,451,946 |
|
- |
|
| Klinger Shannon Thyme |
Chief Legal Officer |
• • – |
2022-12-08 |
4 |
S |
$179.15 |
$87,783 |
D/D |
(490) |
4,772 |
|
- |
|
| Afeyan Noubar |
Director |
– • – |
2022-12-07 |
4 |
AS |
$172.16 |
$1,721,600 |
D/D |
(10,000) |
2,297,209 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-07 |
4 |
AS |
$175.26 |
$7,114,882 |
D/D |
(40,000) |
5,411,946 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-07 |
4 |
OE |
$0.99 |
$39,600 |
D/D |
40,000 |
5,451,946 |
|
- |
|
| Klinger Shannon Thyme |
Chief Legal Officer |
• • – |
2022-12-07 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,139 |
5,262 |
|
- |
|
| Andres Juan |
See remarks |
• • – |
2022-12-07 |
4 |
AS |
$172.16 |
$344,320 |
D/D |
(2,000) |
12,803 |
|
- |
|
| Andres Juan |
See remarks |
• • – |
2022-12-07 |
4 |
OE |
$20.93 |
$41,860 |
D/D |
2,000 |
14,803 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-01 |
4 |
AS |
$173.41 |
$1,734,100 |
I/I |
(10,000) |
6,604,880 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-01 |
4 |
AS |
$179.62 |
$7,239,069 |
D/D |
(40,000) |
5,411,946 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-12-01 |
4 |
OE |
$0.99 |
$39,600 |
D/D |
40,000 |
5,451,946 |
|
- |
|
| Andres Juan |
See remarks |
• • – |
2022-11-30 |
4 |
AS |
$173.52 |
$347,040 |
D/D |
(2,000) |
12,803 |
|
- |
|
| Andres Juan |
See remarks |
• • – |
2022-11-30 |
4 |
OE |
$20.93 |
$41,860 |
D/D |
2,000 |
14,803 |
|
- |
|
| Afeyan Noubar |
Director |
– • – |
2022-11-30 |
4 |
AS |
$173.52 |
$1,735,200 |
D/D |
(10,000) |
2,307,209 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-11-30 |
4 |
AS |
$169.62 |
$6,891,824 |
D/D |
(40,000) |
5,411,946 |
|
- |
|
| Bancel Stephane |
Chief Executive Officer |
• • – |
2022-11-30 |
4 |
OE |
$0.99 |
$39,600 |
D/D |
40,000 |
5,451,946 |
|
- |
|
| Andres Juan |
See remarks |
• • – |
2022-11-29 |
4 |
S |
$173.80 |
$141,475 |
D/D |
(814) |
12,803 |
|
- |
|
| Hoge Stephen |
President |
• • – |
2022-11-29 |
4 |
S |
$173.80 |
$188,576 |
D/D |
(1,085) |
1,627,416 |
|
- |
|
| Andres Juan |
See remarks |
• • – |
2022-11-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,808 |
13,617 |
|
- |
|
1677 Records found
|
|
Page 10 of 68 |
|
|
